DOCSLIB.ORG

Download Investment Profile

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Vanguard® Vanguard® Health Care Fund Product Summary Health care sector fund. Seeks long-term capital appreciation. Invests across industry subsectors and market capitalizations. Invests in health care companies based in the United States and abroad. Fundamental approach. More geographically diversified than most competitors. Quarterly Commentary Note: Company returns may differ if a security was held in the portfolio for less than the full period. The human toll of COVID-19 further mounted during the second quarter of 2021 amid fresh outbreaks of the virus and new variants. The global economy nevertheless continued to rebound sharply if unevenly. Countries that have better succeeded in containing the virus—whether through vaccinations, lockdowns, or People and Process both—tended to fare the best. With the reopening of economies and pent-up demand boosting corporate profits, global stocks Vanguard Health Care Fund seeks long-term capital appreciation finished the quarter significantly higher. U.S. stocks outperformed by investing in stocks broadly representing the health care other developed markets as a whole as well as emerging markets. industry. The advisor seeks to maintain exposure across five primary subsectors: health services, medical products, specialty For the quarter, U.S. stocks returned 8.24%, as measured by the pharmaceuticals, major pharmaceuticals, and international Russell 3000 Index. With large-capitalization stocks leading the markets. Fundamental research focuses on companies with way, the Russell 1000 Index (+8.54%) outpaced the Russell 2000 high-quality balance sheets, strong management, and the potential Index (+4.29%). Although value stocks outperformed growth for new products that will lead to above-average growth in revenue stocks over the first quarter of 2021, that pattern reversed over and earnings. Reflecting the advisor’s contrarian style, stocks may the second quarter, with the Russell 3000 Growth Index be purchased after negative events have caused a decline in share (+11.38%) more than doubling the return of the Russell 3000 Value price. Assets are usually concentrated in the top ten holdings, but Index (+5.16%). the fund remains invested across both subsectors and market Vanguard Health Care Fund outperformed its benchmark, the capitalizations. Because of the industry’s long MSCI All Country World Health Care Index (+9.38%), for the product-development cycle, the advisor pursues a long-term quarter. The fund seeks long-term capital appreciation, focusing on investment approach that has resulted in below-average turnover. domestic and foreign companies engaged in a variety of areas The fund historically has been more geographically diversified than within the health care industry, including pharmaceuticals, medical other health care sector funds. supply, and research. The fund’s investment process uses bottom-up security selection coupled with ongoing evaluation of Wellington Management Company LLP management teams. The fund’s outperformance for the quarter was driven by stock Founded in 1928, Wellington Management Company LLP, Boston, selection in pharmaceuticals. In that industry, a notable Massachusetts, is among the nation’s oldest and most respected overweighting of Eisai (+47%) and lack of exposure to Johnson & institutional investment managers. The firm has advised Vanguard Johnson (+1%) contributed most. A lack of exposure to Moderna Health Care Fund since 1984. (+79%) and an overweight position in Daiichi Sankyo (–23%) Investment Manager Biographies detracted most. For the 12 months ended June 30, the fund lagged its benchmark Jean M. Hynes, CFA, CEO of Wellington Management Company, (+23.48%). Stock selection in biotechnology drove the Managing Partner and Equity Portfolio Manager. Portfolio manager. underperformance, as did selection in North America and the Advised the fund since 2008. Worked in investment management Pacific region. Among the largest detractors were pharmaceutical since 1991. B.A., Wellesley College. company UCB (–9%) and biotech companies Incyte (–19%) and Regeneron (–10%). Strong selection in health care facilities and an overweight allocation to managed health care helped to offset overall underperformance. As of June 30, 2021 Vanguard Health Care Fund Total Returns Expense Year Ratio Quarter to Date 1 Year 3 Years 5 Years 10 Years Health Care Fund Investor Shares (5/23/1984) 0.32% 10.70% 10.38% 20.21% 15.34% 11.85% 14.54% Admiral Shares (11/12/2001) 0.27 10.71 10.40 20.27 15.40 11.91 14.59 Spliced Health Care Index — 9.38 9.86 23.48 15.76 12.36 13.08 Global Health/Biotechnology Funds Average — 8.99 8.20 26.17 17.61 13.95 14.52 The performance data shown represent past performance, which is not a guarantee of future results. Investment returns and principal value will fluctuate, so investors’ shares, when sold, may be worth more or less than their original cost. Current performance may be lower or higher than the performance data cited. For performance data current to the most recent month-end, visit our website at vanguard.com/performance. Figures for periods of less than one year are cumulative returns. All other figures represent average annual returns. Performance figures include the reinvestment of all dividends and any capital gains distributions. All returns are net of expenses. Note: Spliced Health Care Index: S&P 500 Index through December 31, 2001; S&P Health Care Index through May 31, 2010; MSCI All Country World Health Care Index thereafter. Average fund returns are derived from data provided by Lipper, a Thomson Reuters Company. Admiral class shareholders are required to maintain specific minimum balances and meet other special criteria. As of June 30, 2021 Vanguard Health Care Fund Quarterly Returns: Investor Shares Year-End Spliced Health Care Assets Year 1st Quarter 2nd Quarter 3rd Quarter 4th Quarter Health Care Index (Millions) 2021 -0.29% 10.70% — — — — $8,720 2020 -10.98 16.16 4.11% 4.61% 12.62% 14.87% 8,327 2019 7.91 -0.98 -1.53 16.84 22.93 22.67 8,977 2018 0.21 0.52 13.07 -11.18 1.15 1.71 8,315 2017 10.58 6.54 0.97 0.55 19.61 20.14 9,487 2016 -8.84 5.42 0.71 -5.97 -8.99 -6.83 9,550 2015 9.64 3.80 -8.90 8.65 12.65 6.33 12,018 2014 8.84 5.17 3.90 8.06 28.52 18.13 11,252 2013 14.43 5.00 7.56 10.80 43.19 35.76 9,636 2012 7.93 1.38 5.27 -0.07 15.11 17.77 8,143 2011 6.64 8.01 -9.28 6.66 11.45 8.89 8,223 Quarterly Returns: Admiral Shares Year-End Spliced Health Care Assets Year 1st Quarter 2nd Quarter 3rd Quarter 4th Quarter Health Care Index (Millions) 2021 -0.27% 10.71% — — — — $43,001 2020 -10.97 16.18 4.12% 4.62% 12.67% 14.87% 40,704 2019 7.92 -0.96 -1.52 16.85 22.98 22.67 39,149 2018 0.22 0.53 13.08 -11.17 1.21 1.71 35,608 2017 10.59 6.55 0.99 0.56 19.66 20.14 37,667 2016 -8.83 5.43 0.72 -5.95 -8.94 -6.83 33,299 2015 9.66 3.81 -8.89 8.67 12.71 6.33 40,299 2014 8.85 5.18 3.91 8.07 28.57 18.13 33,375 2013 14.44 5.01 7.58 10.81 43.27 35.76 24,142 2012 7.95 1.38 5.29 -0.05 15.17 17.77 14,958 2011 6.65 8.03 -9.28 6.68 11.51 8.89 12,646 As of June 30, 2021 Vanguard Health Care Fund Fund Facts Volatility Measures Investor Admiral R-Squared Beta Shares Shares Spliced Health Care Index 0.95 1.05 Fund Number 0052 0552 DJ US Total Stock Mkt Float Adj Idx 0.65 0.67 Ticker VGHCX VGHAX R-squared and beta are calculated from trailing 36-month fund returns Newspaper Listing HlthCare HlthCareAdml relative to the associated benchmark. CUSIP Number 921908307 921908885 Assets (millions) $8,720 $43,001 (Total $51,721) Top 10 Largest Holdings Inception 5/23/1984 11/12/2001 Expense Ratio (as of 5/2021) 0.32% 0.27% % of Total Net Assets UnitedHealth Group Inc. 5.6% AstraZeneca plc 5.4 Equity Characteristics Pfizer Inc. 5.3 MSCI Eli Lilly & Co. 4.7 ACWI Health Novartis AG 3.7 Health Care Care Bristol-Myers Squibb Co. 3.6 Number of stocks 102 283 Eisai Co. Ltd. 3.4 Median market cap $59.6 Billion $98.1 Billion Boston Scientific Corp. 3.2 Average market cap $102.8 Billion $141.5 Billion Biogen Inc. 3.0 Price/earnings ratio 27.6x 27.9x Anthem Inc. 2.9 Price/book ratio 4.4x 4.9x Total 40.8% Return on equity 13.8% 17.8% The holdings listed exclude any temporary cash investments and equity Earnings growth rate 14.4% 13.4% index products. Equity yield (dividend) 1.1% 1.6% Foreign holdings 27.3% 0.0% Short-term reserves 1.6% — Turnover rate (fiscal year end) 10.9% — As of June 30, 2021 Vanguard Health Care Fund Sector Diversification (% of Stocks) MSCI ACWI Health Overweight/ Health Care Care Underweight Biotechnology 22.1% 14.1% 8.0 Consumer Staples 0.1 0.0 0.1 Financials 0.1 0.0 0.1 Health Care Distributors 0.0 1.3 -1.3 Health Care Equipment 15.3 20.1 -4.8 Health Care Facilities 3.2 1.5 1.7 Health Care Services 1.2 4.0 -2.8 Health Care Supplies 0.6 3.0 -2.4 Health Care Technology 1.4 1.8 -0.4 Life Sciences Tools & Services 6.1 9.3 -3.2 Managed Health Care 11.9 7.8 4.1 Pharmaceuticals 38.0 37.1 0.9 Total 100.0% 100.0% Sector categories are based on the Global Industry Classification Standard (GICS), except for the Other category (if applicable), which includes securities that have not been provided a GICS classification as of the effective reporting period.
Recommended publications
  • Vanguard 2019 Investment Stewardship Semiannual

    Vanguard 2019 Investment Stewardship Semiannual

    Vanguard 2019 Investment Stewardship Semiannual Engagement Update Semiannual Engagement Update Introduction 1 Board composition 2 Oversight of strategy and risk 6 Executive compensation 8 Governance structures 10 Company engagements 12 b Good governance can enhance and protect shareholder value over time. Boards that are well-composed for today and tomorrow have independent, experienced, and diverse members capable of overseeing strategy, governing risk, setting appropriate compensation, and embracing policies that give voice to shareholders. One of the hallmarks of good governance is engagement with shareholders. Each year, on behalf of Vanguard funds, our Investment Stewardship team meets with hundreds of portfolio companies. In these interactions, we have open, constructive dialogues about corporate governance. This semiannual engagement update provides snapshots of some of the discussions we held in the six months ended December 31, 2018. The substance of those discussions was framed by Vanguard’s four principles of corporate governance: Board Oversight of Executive Governance composition strategy & risk compensation structures These pillars cover topics such as board independence, alignment of strategy to long-term value creation, and linkage of pay to performance. Although these discussions can vary widely by company, sector, and region, our engagements tend to fall into three broad categories. Strategic engagements are meetings in which we learn about—but don’t seek to direct—a company’s long- term strategy. These enable us to understand the board’s approach to overseeing and aligning governance practices with the company’s long-term goals. Event-driven engagements focus on specific ballot items—often contentious—or a leadership change or company crisis.
  • Q1 Pharma Sector Snapshot

    Q1 Pharma Sector Snapshot

    SPECIALTY & GENERIC PHARMA Q1 2021 Report Market Commentary – Debt Capital Markets Debt Markets ▪ 2020 saw increased amounts of debt used in buyouts across the board, resulting in the highest debt / EBITDA Median US Buyout Multiples levels since 2014 − The increased use of debt was driven by 2H20 back- end loaded lending activity (primarily 4Q20) as 16.0x 12.7x 14.1x 12.2x 12.0x 11.6x 11.5x certainty around the U.S. election and vaccination 11.1x 10.0x 9.8x 12.0x 9.7x expectations increased 9.4x 8.6x 8.3x 8.2x 7.5x 7.8x 5.2x 6.7x 5.7x 5.6x ▪ 8.0x 5.9x As the effects of COVID now begin to diminish, debt 5.4x 4.4x 4.1x 3.7x 4.6x 4.3x 3.8x markets have seemingly recovered, signaling that 3.6x lenders have become increasingly comfortable with 4.0x 4.3x 6.9x 6.5x 6.3x 6.0x 5.9x 5.7x 5.7x 5.7x 5.7x 5.6x 5.3x 4.5x 4.4x macroeconomic and company-specific fundamentals 4.3x 0.0x 3.2x − With increased confidence, lenders are currently looking to provide strong leverage for high-quality assets, particularly ones that have proven their Debt/EBITDA Equity/EBITDA EV/EBITDA stability through the recent market downturn Source: PitchBook ▪ The spread on U.S. high-yield debt has returned to pre- Historical US High Yield Debt Effective Yield COVID levels − 4.22% current effective yield compared with a 12.0% 11.4% 11.38% effective yield on March 23, 2020 (peak of the pandemic) 9.0% ▪ We expect increased activity by lenders in 2021 due to: 6.0% 4.2% − Pent-up demand in M&A activity driven by the impact of COVID 3.0% − Limited Partner agreements and investor
  • Eli Lilly and Company

    Eli Lilly and Company

    Merrimack College Merrimack ScholarWorks Honors Senior Capstone Projects Honors Program Spring 2021 Eli Lilly and Company Alyssa Ardai Follow this and additional works at: https://scholarworks.merrimack.edu/honors_capstones Part of the Business Commons Ardai 1 Written Assignment #4 Eli Lilly and Company Alyssa Ardai Bus 4402W: Strategic Analysis and Decision Making Professor Herrmann April 30, 2021 Ardai 2 Abstract Eli Lilly and Company is a pharmaceutical company that has the goal of creating new products. Eli Lilly’s products are seen in hospitals and pharmacies around the US, with the hopes of growing internationally. By having a large number of drugs in their pipeline, they can be a key player in improving multiple types of illnesses as well as help aid the aging population. The healthcare sector is always one that is high-performing. Ardai 3 Eli Lilly and Company is positioned as a pharmaceutical company, with the goal of creating high-quality medicine for every need or to take a preexisting medicine and make it better. For the past 140 years, they have been creating medicine for various causes, but are now focusing their efforts on antibody treatments for the COVID-19 pandemic, as well as different cancers and autoimmune diseases. Everything that the company does should follow its core values: integrity, excellence, and respect for people (Eli Lilly and Company - A). Eli Lilly is found in the US, Japan, Europe, and hopes to expand to the rest of the world soon. They are broken down into Endocrinology, Oncology, Immunology, Neuroscience, & Other. The company has increased revenues from $23,832.8 - $25,925.3, a consistent tax rate of 15%, expenses increasing $300k a year, accounts receivable, or a/r, decreasing as they pay less in patents and drugs go generic, consistent inventory of $120k - $140k, showing they do not keep a lot on hand, a weighted average cost of capital, or WACC, of 5.9% showing it does not hold a lot of debt, and a long term growth rate of 2.3%, showing a healthy but stable growth (Bloomberg LP, CapitalIQ 2021).
  • Combination Medications

    Combination Medications

    Combination Medications WHAT ARE COMBINATION MEDICATIONS? Combination medications are pills, tablets, or injections that contain more than one medication to treat HIV. They are listed in the tables below. Pharmaceutical companies have been working hard to make their medications easier to take. Part of this effort has been to combine more than one medication into a single pill. These combinations are referred to as fixed-dose combinations (FDCs). Combinationantiretroviral therapy (ART), sometimes called highly active antiretroviral therapy (HAART), has revolutionized the management of HIV infection and rendered it a chronic manageable disease. The first FDC to treat HIV wasCombivir , manufactured by ViiV Healthcare. Combivir contains two nucleoside reverse transcriptase inhibitors (NRTIs): lamivudine and zidovudine. This was followed byTrizivir , also manufactured by ViiV Healthcare. Trizivir includes three NRTIs:abacavir , lamivudine, and zidovudine. Both Combivir and Trizivir are no longer widely used in the U.S. due to the frequency and severity of side effects. Be sure that you do not take a combination medication along with any of its components!For example, do not take Truvada (which contains emtricitabine and tenofovir DF) with tenofovir DF (Viread) or emtricitabine (Emtriva). Your healthcare provider will help you decide which HAART regimen is best for you; take your medications exactly as your healthcare provider tells you to. TABLE OF COMBINATION HIV MEDICATIONS Brand name Year Approved Individual Components Also Known As Manufacturer
  • THE VOICE of CHESTER COUNTY Voice MARCH 2015

    THE VOICE of CHESTER COUNTY Voice MARCH 2015

    the THE VOICE OF CHESTER COUNTY Voice MARCH 2015 The Chester County Chamber Foundation Gala A night of fun for a great cause! Last Saturday the Chester County Chamber Foundation hosted the 2015 Auction Gala and what a night it was! Gala attendees put on their most fashionable 1960’s outfits and made their way to White Manor Country Club. Upon arrival, guests were greeted with champagne and appetizers. Between networking and catching up with friends, ordering a signature drink and checking out the Silent Auction-- the buzz coming from cocktail hour was remarkable. As the ballroom doors opened, guests were led to the Wine Wall, photo booth, and delicious food stations. It wasn’t long before the Smooth Sounds of Steve Silicato had everyone on the dance floor. Amongst all the good times, it was important to remember why we were there. All the proceeds from the raffles, games, and Live & Silent auctions will fund our Youth Leadership Program. Thank you to all who came to support this event and our mission at the Chamber Foundation. 1 Join the Chamber at our Annual State of the County Luncheon Featuring Chester County Commissioners Terence Farrell, Michelle Kichline, and Kathi Cozzone, CCCBI hosts the Chester County Commissioners for our State of the County Luncheon on Wednesday, April 8th. This event provides an update on Chester County and draws hundreds of business and community leaders. We’ll be honoring the recipient of the Boling Award, presented to a person who exemplifies the meaning of a dedicated public servant who excelled in his accomplishments on behalf of the public.
  • Big Pharma Freshens Up

    Big Pharma Freshens Up

    April 09, 2021 Big pharma freshens up Amy Brown Reliance on established drugs lessened for most large drug makers last year, but staleness is creeping in at Merck and Bristol. All successful drug franchises must one day fade – the challenge comes in finding replacements. It is encouraging therefore to see that almost all major developers improved on the sales freshness index last year, versus 2019, with a couple of notable exceptions. This percentage measure is derived from the proportion of a company’s prescription drug sales that come from products more than 10 years old. Scores range widely within the cohort, showing that some groups have much more work to do than others. Take Abbvie, with 74% of 2020’s drug sales derived from drugs at least a decade old, compared with a much fresher Astrazeneca, at 44%. Abbvie is still very reliant on its mega-blockbuster Humira – the autoimmune antibody contributed 44% of the company’s drugs sales last year – and the big pharma group’s freshness score has not shifted from 2019, when Evaluate Vantage last ran these numbers (Sanofi's geriatric pipeline fails to freshen up, January 22, 2020). Astrazeneca was at the other end of the scale last time and its performance improved again in 2020. The previous laggard Sanofi, meanwhile, has the huge success of Dupixent to thank for its big shift towards the fresher end of the group. The French company’s departure from the top of the table leaves Abbvie, Pfizer and Roche as the stalest big pharma groups, and arguably under the most pressure to find new sales sources.
  • Valeant Pharmaceuticals International, Inc. 2012 Annual Report Valeant Inc

    Valeant Pharmaceuticals International, Inc. 2012 Annual Report Valeant Inc

    Valeant Pharmaceuticals International, Inc. 2012 Annual Report Valeant Pharmaceuticals International, Inc. 2012 Annual Report Valeant Gathering Momentum Company Overview Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical company that develops and markets prescription and non-prescription pharmaceutical products that make a meaningful difference in patients’ lives. Valeant’s primary focus is principally in the areas of dermatology and neurology. The Company’s growth strategy is to acquire, develop and commercialize new products through strategic partnerships, and build on the company’s strength in dermatology and neurology. Valeant plans to strategically expand its pipeline by adding new compounds or products through product or company acquisitions and will maximize its pipeline through strategic partnering to optimize its research and development assets and strengthen ongoing internal development capabilities. Valeant’s strategic markets are primarily in the United States, Canada, Central and Eastern Europe, Latin America, Australia and South East Asia. Headquartered in Montreal, Quebec, Valeant has approximately 7,000 employees worldwide. FORWARD-LOOKING Statements In addition to current and historical information, this Annual Report contains forward-looking statements, including, without limitation, statements regarding our strategy, expected future revenue, the prospects for approval of product candidates and the timing of regulatory approvals, and the growth and future development of the company, its business units and its products. Words such as “expects,” “anticipates,” “intends,” “plans,” “should,” “could,” “would,” “may,” “will,” “believes,” “estimates,” “potential,” or “continue” or similar language identify forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties. Our actual results may differ materially from those contemplated by the forward-looking statements.
  • Proxy Statement 2021

    Proxy Statement 2021

    Purpose Blueprint OUR PURPOSE Breakthroughs that change patients’ lives OUR BOLD MOVES 1. Unleash the 2. Deliver 3. Transform our 4. Win the 5. Lead the power of our first-in-class go-to-market digital race conversation people science model in pharma OUR BIG IDEAS 1.1 Create room for 2.1 Source the best 3.1 Improve access 4.1 Digitize drug 5.1 Be known as the meaningful work science in the through new payer discovery and most patient- 1.2 Recognize both world partnerships development centric company leadership and 2.2 Double our 3.2 Address the 4.2 Enhance health 5.2 Drive pro- performance innovation success patient outcomes and innovation/pro- 1.3 Make Pfizer an rate affordability patient experience patient policies amazing 2.3 Bring medicines to challenge 4.3 Make our work 5.3 Focus the narrative workplace for all the world faster 3.3 Transform the way faster and easier on the value of our we engage science patients and physicians OUR VALUES Courage Excellence Equity Joy A Letter from Pfizer’s Chairman & Chief Executive Officer To Our Shareholders: 2020 was a year like none other in Pfizer’s history – defined by bold decisions, even bolder actions and incredible results. With the separation of Upjohn, we created a company that was 20% smaller, but more focused than ever on delivering first-in-class science for the benefit of patients. Through our collaboration with BioNTech, we delivered a breakthrough COVID-19 vaccine in less than a year. And by harnessing the power of a variety of digital capabilities – as well as our own steadfast commitment to patients – we made sure that despite lockdowns and travel restrictions, we continued to reach more than 400 million patients worldwide with our medicines and vaccines.
  • Vanguard Money Market Funds Annual Report August 31, 2018

    Vanguard Money Market Funds Annual Report August 31, 2018

    Annual Report | August 31, 2018 Vanguard Money Market Funds Vanguard Prime Money Market Fund Vanguard Federal Money Market Fund Vanguard Treasury Money Market Fund Vanguard’s Principles for Investing Success We want to give you the best chance of investment success. These principles, grounded in Vanguard’s research and experience, can put you on the right path. Goals. Create clear, appropriate investment goals. Balance. Develop a suitable asset allocation using broadly diversified funds. Cost. Minimize cost. Discipline. Maintain perspective and long-term discipline. A single theme unites these principles: Focus on the things you can control. We believe there is no wiser course for any investor. Contents Your Fund’s Performance at a Glance. 1 CEO’s Perspective. 3 Advisor’s Report. 5 Prime Money Market Fund. .7 Federal Money Market Fund. 26 Treasury Money Market Fund. 42 About Your Fund’s Expenses. 55 Trustees Approve Advisory Arrangements. .57 Glossary. 59 Please note: The opinions expressed in this report are just that—informed opinions. They should not be considered promises or advice. Also, please keep in mind that the information and opinions cover the period through the date on the front of this report. Of course, the risks of investing in your fund are spelled out in the prospectus. See the Glossary for definitions of investment terms used in this report. Your Fund’s Performance at a Glance • For the 12 months ended August 31, 2018, Vanguard Prime Money Market Fund returned 1.59% for Investor Shares and 1.66% for Admiral Shares. Vanguard Federal Money Market Fund returned 1.42% and Vanguard Treasury Money Market Fund 1.43%.
  • Vanguard® Value Index Fund

    Vanguard® Value Index Fund

    Vanguard® Vanguard® Value Index Fund Product Summary Vanguard Style View : Large Value Seeks to track the performance of the CRSP US Large Cap Value Index portfolio of large-capitalization value stocks. Index. Investment style Value Blend Growth Large-cap value equity. Passively managed, full-replication approach. Large Fund remains fully invested. Mid Low expenses minimize net tracking error. Small Note: The Investor Shares are closed to new investors. Market capitalization Central tendency Expected range of fund holdings Quarterly Commentary People and Process The human toll of COVID-19 further mounted during the second Vanguard Value Index Fund seeks to track the investment quarter of 2021 amid fresh outbreaks of the virus and new performance of the CRSP US Large Cap Value Index, an variants. The global economy nevertheless continued to rebound unmanaged benchmark representing U.S. large-capitalization value sharply if unevenly. Countries that have better succeeded in stocks. The fund attempts to replicate the target index by containing the virus—whether through vaccinations, lockdowns, or investing all, or substantially all, of its assets in the stocks that both—tended to fare the best. With the reopening of economies make up the index, holding each stock in approximately the same and pent-up demand boosting corporate profits, global stocks proportion as its weighting in the index. The experience and finished the quarter significantly higher. U.S. stocks outperformed stability of Vanguard’s Equity Index Group have permitted other developed markets as a whole as well as emerging markets. continuous refinement of techniques for reducing tracking error. The group uses proprietary software to implement trading The combination of faster economic growth, a recovery in decisions that accommodate cash flow and maintain close commodity prices, ongoing fiscal and monetary stimulus, and a correlation with index characteristics.
  • Vanguard Balanced Portfolio Semiannual Report

    Vanguard Balanced Portfolio Semiannual Report

    Semiannual Report | June 30, 2021 Vanguard Variable Insurance Funds Balanced Portfolio Contents About Your Portfolio’s Expenses ..................... 1 Financial Statements ................................ 3 Trustees Approve Advisory Arrangement ............31 Liquidity Risk Management..........................32 About Your Portfolio’s Expenses As a shareholder of the portfolio, you incur ongoing costs, which include costs for portfolio management, administrative services, and shareholder reports (like this one), among others. Operating expenses, which are deducted from a portfolio's gross income, directly reduce the investment return of the portfolio. A portfolio's expenses are expressed as a percentage of its average net assets. This figure is known as the expense ratio. The following examples are intended to help you understand the ongoing costs (in dollars) of investing in your portfolio and to compare these costs with those of other mutual funds. The examples are based on an investment of $1,000 made at the beginning of the period shown and held for the entire period. The accompanying table illustrates your portfolio's costs in two ways: • Based on actual portfolio return. This section helps you to estimate the actual expenses that you paid over the period. The ”Ending Account Value“ shown is derived from the portfolio's actual return, and the third column shows the dollar amount that would have been paid by an investor who started with $1,000 in the portfolio. You may use the information here, together with the amount you invested, to estimate the expenses that you paid over the period. To do so, simply divide your account value by $1,000 (for example, an $8,600 account value divided by $1,000 = 8.6), then multiply the result by the number given for your portfolio under the heading ”Expenses Paid During Period.“ • Based on hypothetical 5% yearly return.
  • February 2021 EPS Pipeline Report

    February 2021 EPS Pipeline Report

    Pipeline Report February 2021 Pipeline Report February 2021 © 2021 Envolve. All rights reserved. Page 1 This quarterly at-a-glance publication is developed by our Clinical Pharmacy Drug Information team to increase your understanding of the drug pipeline, Table of Contents ensuring you’re equipped with insights to prepare for shifts in pharmacy benefit management. In this issue, you’ll learn more about key themes and notable drugs referenced in the following points. COVID-19 1 > Veklury is currently the only agent that is FDA-approved for the treatment of COVID-19. Three additional therapeutics and two vaccines have been granted Emergency Use Authorization (EUA), and at least three more vaccines are Recent Specialty Drug Approvals1 4 expected to receive an EUA in the relatively near future. > The previous quarter noted the approval of several breakthrough therapies for rare or ultra-rare conditions, which previously had no available FDA-approved Recent Non-Specialty Drug Approvals 9 treatments — Zokinvy for Hutchinson-Gilford progeria syndrome and progeroid laminopathies, Oxlumo for primary hyperoxaluria type 1, and Imcivree for genetically mediated obesity. Upcoming Specialty Products 10 > Other notable approvals include: Lupkynis — the first oral therapy approved for lupus nephritis; Orladeyo — the first oral therapy approved as prophylaxis of hereditary angioedema attacks;Cabenuva – the first long-acting injectable antiretroviral therapy intended as maintenance treatment of HIV; and Breyanzi — Upcoming Non-Specialty Products 18 the